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Background
Hereditary nonpolyposis colorectal cancer (HNPCC) is
hallmarked by microsatellite instability. The prognosis of
HNPCC-related colon cancer is well characterized, but
little is known about rectal cancers. The aim of this
study was to report the long-term outcomes of
HNPCC-related rectal cancer where current-era multi-
modality therapy was utilized.
Methods
Patients referred to our institution for either primary or
recurrent rectal cancer between 1992-2010 were identi-
fied based on following inclusion criteria: 1) pathogenic
germline mutation in DNA mismatch repair genes
(MMR; n=19); 2) germline variants of uncertain signifi-
cance but tumor studies suggestive of MMR (n=6); 3)
suggestive tumor studies but negative germline testing
(n=5); and 4) suggestive tumor studies but no germline
testing (n=4). Patients were reviewed for clinical charac-
teristics and treatments, and followed to death or last
contact.
Results
Among the 34 patients, 21 (62%) were female. The
median age at diagnosis of rectal cancer was 40 (range:
20-72). In 28 patients (82%), this was the index cancer
leading to the diagnosis of HNPCC, and in 22 patients
(65%), this was their first malignancy. Only a minority
satisfied Amsterdam I (21%) or Amsterdam II (21%)
criteria, while nearly all (94%) met the revised
Bethesda criteria. Pathogenic mutations included
MLH1 (15%), MSH2 (32%) and MSH6 (9%). The
majority (67%) presented with locally advanced (T3/T4
and/or node positive, n=20) or metastatic disease
(n=3), and 50% received neoadjuvant radiation with 5-
FU based chemotherapy. Final pathologic stages are as
outlined below. Patients underwent proctectomy (65%),
total/near total coloproctectomy (21%), transanal exci-
sion (9%), and chemoradiation only (3%). Multivisceral
resection was required in 9 patients (28%) and adju-
vant therapy was given in 24 (71%). After a median fol-
lowup of 4.1 years, 94% were alive. Six patients
developed local-regional (n=3) or distant (n=3) disease
recurrence, and 5 underwent successful surgical sal-
vage. Metachronous CRC was found in 4 patients
(12%) after a median of 8 years (range: 3.2-17), and all
were amenable to surgical resection. The estimated 5-
year freedom from recurrent or metachronous CRC
was 76%. The 5-year overall survival was 93%, which
was preserved at 10-years. Table 1.
Discussion
Rectal cancer may present as the index cancer for
HNPCC over a wide age range. Despite advanced stages
at presentation, excellent long-term prognosis can be
expected with aggressive multimodality therapy. Vigilant
surveillance for recurrent or metachronous CRC should
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Table 1
Pathologic
Stage
After neoadjuvant
(n=17)
No neoadjuvant
(n=17)
Total
(n=50)
0 5 (29%) 2(12%) 7 (21%)
I 2 (12%) 6 (35%) 8 (24%)
II 4 (24%) 5 (29%) 9 (26%)
III 5 (29%) 2 (12%) 7 (21%)
IV 1 (6%) 1 (3%)
Unknown 2 (12%) 2 (5%)
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repeat surgical salvage and preserved long-term survival.
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